In a meta-analysis [94] of 7 RCTs (data from 54,092 adults with T2D; 84% without HF, of whom 8,460 using GLP-1 RA), GLP-1 RA reduced the risk of hHF or CV death (HR 0.84, 95% CI 0.76 to 0.92) and ACM (HR 0.85, 95% CI 0.79 to 0.92). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.